Chiesi has invested €430 million in a new facility in Italy, aiming to bolster its production capabilities. Meanwhile, Bharat Biotech has inaugurated its first cell and gene therapy (CGT) site in India, marking a significant advancement in the region’s biopharmaceutical landscape.
SNBL and Tasso, Inc. have announced a strategic joint venture in Japan aimed at advancing innovative healthcare solutions. This collaboration is set to enhance patient accessibility to advanced diagnostic tools in the region, strengthening both companies’ market presence.
Eli Lilly’s recent launch of its weight-loss drug in India is set to transform the competitive landscape of the burgeoning market. With obesity rates rising, rivals are now poised to accelerate their efforts to capture a share of this lucrative opportunity.
A recent Lancet report highlights a groundbreaking cancer therapy that has shown promising results, achieving a 73% success rate in clinical trials among Indian patients. This significant finding could revolutionize treatment options in India and beyond.
China has implemented a ban on imports of Illumina’s gene sequencing machines, shortly after the U.S. reinstated tariffs on certain products. This move highlights escalating tensions between the two nations in the field of biotechnology and trade.
